Clarus Therapeutics Shares Rise 27% on New U.S. Patents

By Chris Wack

Clarus Therapeutics Holdings Inc. shares were up 27% to $6.62 Tuesday after the company said the U.S. Patent and Trademark Office issued two new patents for claims that cover its oral testosterone replacement product, Jatenzo testosterone undecanoate.

The company said the patent entitled "Oral Testosterone Ester Formulations and Methods of Treating Testosterone Deficiency Comprising Same" and the patent entitled "Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same" both cover Jatenzo, and will expire in 2030 and 2026, respectively.

Clarus said Jatenzo is the first and only Food and Drug Administration-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions.

Clarus said it plans to list these patents in the FDA's Orange Book, which would bring the total number of Orange Book-listed patents covering Jatenzo to seven.

Volume for the stock was 8.6 million shares at 10 a.m. ET, compared with 65-day average volume of 2.4 million shares.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

November 30, 2021 10:19 ET (15:19 GMT)

Clarus Therapeutics (NASDAQ:CRXT)
Historical Stock Chart
From Aug 2024 to Sep 2024